Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Alnylam Pharmaceuticals, Inc. ALNY

Healthcare — Biotechnology

Alnylam Pharmaceuticals, Inc. (ALNY) Business Profile

Company Overview

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a leading biopharmaceutical company specializing in the development and commercialization of RNA interference (RNAi) therapeutics. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has been at the forefront of RNAi technology, a groundbreaking approach to treating diseases by silencing specific genes responsible for disease progression. The company was co-founded by a group of prominent scientists, including Phillip Sharp, a Nobel laureate in Physiology or Medicine.

The company’s leadership team is spearheaded by CEO Yvonne Greenstreet, who took over the role in 2022. Greenstreet brings extensive experience in the pharmaceutical and biotechnology sectors, ensuring Alnylam continues to innovate and expand its portfolio. Other key executives include Akshay Vaishnaw, President of R&D, and Jeff Poulton, Chief Financial Officer. Alnylam’s mission is to harness the power of RNAi to transform the lives of patients with rare and debilitating diseases.

Core Business Segments

Alnylam Pharmaceuticals operates primarily in the field of RNAi therapeutics, focusing on developing treatments for rare genetic diseases, cardio-metabolic diseases, and central nervous system (CNS) disorders. The company’s product portfolio is categorized into the following major segments:

1. Rare Genetic Diseases

Alnylam has developed several groundbreaking therapies targeting rare genetic disorders. Key products in this category include:

  • ONPATTRO® (patisiran): Approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy.
  • GIVLAARI® (givosiran): Designed for the treatment of acute hepatic porphyria (AHP).
  • OXLUMO® (lumasiran): Approved for the treatment of primary hyperoxaluria type 1 (PH1).

2. Cardio-Metabolic Diseases

Alnylam is expanding its portfolio to address cardio-metabolic conditions, leveraging RNAi technology to target diseases with significant unmet medical needs. Key products include:

  • AMVUTTRA® (vutrisiran): A next-generation RNAi therapeutic for the treatment of hATTR amyloidosis.
  • Inclisiran (partnered with Novartis): A treatment for hypercholesterolemia, targeting PCSK9 to lower LDL cholesterol levels.

3. Central Nervous System (CNS) and Ocular Diseases

Alnylam is actively exploring RNAi applications in CNS and ocular diseases. While these programs are in earlier stages of development, they represent a significant growth opportunity for the company.

Business Model

Alnylam’s business model is built around the discovery, development, and commercialization of RNAi therapeutics. The company integrates cutting-edge science with a patient-centric approach to deliver innovative treatments. Key aspects of its business model include:

  • Research and Development (R&D): Alnylam invests heavily in R&D to maintain its leadership in RNAi technology. The company collaborates with academic institutions and industry partners to accelerate innovation.
  • Strategic Partnerships: Alnylam has established partnerships with major pharmaceutical companies, including Novartis, Regeneron, and Sanofi, to co-develop and commercialize RNAi therapies.
  • Revenue Generation: The company generates revenue through product sales, licensing agreements, and milestone payments from its partners.
  • Global Reach: Alnylam has a strong presence in North America, Europe, and Asia, ensuring its therapies are accessible to patients worldwide.

Strategic Direction

Alnylam is committed to expanding its RNAi platform and addressing a broader range of diseases. Key strategic priorities include:

  • Pipeline Expansion: The company is advancing its pipeline with a focus on CNS and ocular diseases, as well as additional cardio-metabolic and rare genetic conditions.
  • Geographic Expansion: Alnylam aims to increase its global footprint by entering new markets and strengthening its presence in existing ones.
  • Sustainability Goals: The company is dedicated to environmental sustainability and aims to reduce its carbon footprint through eco-friendly practices.
  • Patient-Centric Approach: Alnylam continues to prioritize patient access and affordability, ensuring its therapies reach those in need.

Competitive Landscape

Alnylam operates in a highly competitive biopharmaceutical industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Ionis Pharmaceuticals: A leader in antisense technology, offering therapies that compete with Alnylam’s RNAi-based treatments.
  • Moderna and BioNTech: Companies specializing in mRNA technology, which has applications overlapping with RNAi.
  • Pfizer and Novartis: Large pharmaceutical companies with significant resources and competing products in cardio-metabolic and rare disease segments.

Despite the competition, Alnylam’s proprietary RNAi platform and first-mover advantage position it as a leader in the field.

Risk Factors

Alnylam faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its approved products, particularly ONPATTRO, GIVLAARI, and OXLUMO.
  • Regulatory Challenges: The biopharmaceutical industry is subject to stringent regulatory requirements, which could delay product approvals.
  • Supply Chain Disruptions: Global supply chain issues could affect the production and distribution of Alnylam’s therapies.
  • Competition: The emergence of new technologies and competitors could erode Alnylam’s market share.
  • Financial Risks: As a growth-stage company, Alnylam may face challenges in achieving profitability while continuing to invest in R&D.

Recent Developments

Alnylam has made significant progress in recent years, including:

  • FDA Approvals: The approval of AMVUTTRA in 2022 marked a major milestone for the company.
  • Pipeline Advancements: Alnylam has initiated clinical trials for several new RNAi therapies targeting CNS and ocular diseases.
  • Strategic Partnerships: The company expanded its collaboration with Regeneron to develop RNAi therapeutics for CNS disorders.
  • Global Expansion: Alnylam has launched its products in new markets, including Asia and Latin America.

Investment Considerations

Investors considering Alnylam should weigh the following factors:

Strengths:

  • Innovative Platform: Alnylam’s proprietary RNAi technology gives it a competitive edge.
  • Strong Pipeline: A robust pipeline of therapies targeting high-value markets.
  • Strategic Partnerships: Collaborations with industry leaders enhance its growth potential.

Risks:

  • High R&D Costs: Significant investment in R&D could impact profitability.
  • Regulatory Risks: Delays in product approvals could affect revenue growth.
  • Market Competition: Intense competition from established and emerging players.

Conclusion

Alnylam Pharmaceuticals is a pioneer in RNAi therapeutics, with a strong portfolio of approved products and a promising pipeline. The company’s innovative platform, strategic partnerships, and patient-centric approach position it for long-term success. While challenges remain, including regulatory and competitive risks, Alnylam’s leadership in RNAi technology and commitment to addressing unmet medical needs make it a compelling player in the biopharmaceutical industry.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us